Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Cell/Gene Tx channel feed
Bristol-Myers is making a bee-line to the FDA with positive liso-cel data — but is it too late in the CAR-T game?
6 years ago
R&D
Patient #9 has been a concern, but Sangamo and Pfizer are bullish about winning the marathon hemophilia A gene therapy race
6 years ago
R&D
J&J team shows off 'breakthrough' BCMA CAR-T data, and that could cause a big headache at bluebird and Bristol-Myers
6 years ago
R&D
With FDA review of its gene therapy underway, Ferring's $570M spinout delivers in PhIII bladder cancer readout
6 years ago
R&D
Novartis, Vertex outline big gene therapy plans — fueling a global boom
6 years ago
In a landmark first glimpse of human data from Vertex, CRISPR/Cas9 gene therapy signals early benefit
6 years ago
R&D
Sarepta picks up a slate of preclinical gene therapy programs, seeding new StrideBio deal with $48M upfront
6 years ago
Deals
FDA puts Solid Bio’s lead gene therapy program on hold — again — after another patient is hurt by SGT-001
6 years ago
R&D
Decrying 'arbitrary and capricious' action, RegenxBio sues FDA over clinical holds on gene therapy
6 years ago
FDA+
RegenxBio runs into partial hold for anti-VEGF gene therapy as FDA investigates delivery device
6 years ago
FDA+
Thermo Fisher hooks gut onto its gene therapy pipeline, inks new collaboration pact
6 years ago
Novartis takes a hit as FDA orders a hold on Zolgensma trials in wake of fresh safety concerns
6 years ago
Pharma
FDA+
Sean Parker helps create a CRISPRed cell therapy 2.0 play — and he’s got a high-profile set of leaders on the team
6 years ago
Financing
Startups
Exclusive: GSK’s Hal Barron allies with Rick Klausner’s $600M cell therapy startup, looking to break new ground blitzing solid tumors
6 years ago
Deals
Ness Bermingham looks to lead the wave of RNA editing at new Atlas upstart Korro Bio
6 years ago
Startups
Early functional data on limb girdle patients buoy expectations for Sarepta's gene therapy
6 years ago
R&D
Regeneron doubles down on partner Adicet's gamma delta T cell tech in $80M financing
6 years ago
Financing
San Francisco biotech has its heart in heart failure — and $92M in the bank
6 years ago
Startups
ARC-T? Alternative CAR-T startup bags $85M for clinical quest to redirect 'blind hunter' T cells
6 years ago
Startups
Neoantigen player PACT Pharma woos Tim Moore from Kite to run technical ops
6 years ago
People
The time is now: John Cox assumes CEO post at Flagship-backed Torque, steering cell therapy to clinical trials
6 years ago
People
Regulators throw up another hurdle to Roche’s $4.3B Spark acquisition as questions percolate over hemophilia market domination
6 years ago
Deals
Novartis accuses 2 AveXis founders of altering data, stonewalling probe — but ex-CSO blasts back
6 years ago
Pharma
FDA+
Zolgensma didn't cause an infant death, AveXis execs say as they spotlight long-term data
6 years ago
R&D
Pharma
First page
Previous page
49
50
51
52
53
54
55
Next page
Last page